中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (11): 2399-2400.doi: 10.4103/1673-5374.369112

• 观点:退行性病与再生 • 上一篇    下一篇

小胶质细胞己糖酶2缺乏通过脂质代谢增加ATP的生成,导致β-淀粉样蛋白清除

  

  • 出版日期:2023-11-15 发布日期:2023-05-04

Role of the adipocyte immune brain axis in Parkinson’s disease: friend or foe?

Martin Regensburger,  Thomas M. Kinfe*   

  1. Division of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany (Regensburger M)
    Center for Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany (Regensburger M)
    Division of Functional Neurosurgery and Stereotaxy, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany (Kinfe TM)
  • Online:2023-11-15 Published:2023-05-04
  • Contact: Thomas M. Kinfe, MD, PhD, thomasmehari.kinfe@uk-erlangen.de or thomas.mehari.kinfe@fau.de.
  • Supported by:
    MR is a fellow of the Clinician Scientist Programme (IZKF, University Hospital Erlangen) and is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; 270949263/ GRK2162) and the BMBF funded TreatHSP consortium (01GM1905B).

摘要: https://orcid.org/0000-0002-4888-543X (Thomas M. Kinfe) 

Abstract: The classical role of adipocytokines is a negative feedback mechanism, providing information about bodily energy reserves to the brain, and thus controlling satiety and food intake (Campfield et al., 1995). Adipose tissue forms the largest endocrine organ of the body. After the initial description of leptin and its receptor, LEPR/OBR, with its main active isoform OBRb, there was an initial hope for a drugable pathway to counteract the increasing burden of overweight/adiposity, metabolic syndrome, and related disorders (Figure 1). Compensatory pathways and tolerance effects, however, preclude a metabolic intervention using recombinant adipocytokines in metabolic syndrome. Leptin, for example, is increased in adiposity and metabolic syndrome. Nevertheless, recombinant leptin has been approved for leptin deficiency-associated lipodystrophy in the US.